### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average burden					
ours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	)													
1. Name and Address of Reporting Person * OMara Patrick J.				2. Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]						5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BLVD., SUITE 130				3. Date of Earliest Transaction (Month/Day/Year) 01/19/2017						X Officer (give title below) Other (specify below)  SVP, Business Development					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
NEWARK	<u> </u>										_ Point fried by i	Tore than One N	eporting reison		
(City)	1	(State)	(Zip)	Table I - Non-Derivative Securities Acqui						s Acquire	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if r) any (Month/Day/Year)		ate, if Co	(Instr. 8)		A. Securities Acq A) or Disposed of Instr. 3, 4 and 5)  (A) or (D)	of (D) Ov Tra				Ownership o	eneficial wnership		
Reminder: R	eport on a se	eparate line for each	class of securities	beneficial	lly o	wned dire	ctly o	Person contain	y. ns who respon ned in this for isplays a curre	m are no	t required t	o respond	l unless the		174 (9-02)
									osed of, or Bene invertible secur		wned				_
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Ex Month/Day/Year) an	A. Deemed execution Date, if ny Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date E: Expiration (Month/D		7. Title a of Under Securitie (Instr. 3 a	s	8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivative Security: Direct (D) or Indirect (s) (I)	
				Code	V	(A)	(D)	Date Exercisab	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (right to buy)	\$ 1.72	01/19/2017		Α		100,000	)	(1)	01/18/2027	Commo	on 100,000	\$ 0	100,000	D	
Report	ting O	wners				Relation	ships			Ī					

Reporting Owner Name / Address		Relationships						
		10% Owner	Officer	Other				
OMara Patrick J. C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BLVD., SUITE 130 NEWARK, CA 94560			SVP, Business Development					

# **Signatures**

/s/ Sujal Shah, by power of attorney	01/23/2017
Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.